Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...
Oppenheimer maintains Veru stock Outperform rating, $5 target
Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the announcement of encouraging trial results. With the stock currently trading at $0.
FierceBiotech3d
Veru's drug conserves muscle mass for older patients taking Novo's Wegovy in phase 2 trial
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
Barclays PLC Purchases 139,617 Shares of Veru Inc. (NASDAQ:VERU)
Barclays PLC lifted its position in shares of Veru Inc. (NASDAQ:VERU – Free Report) by 309.2% during the 3rd quarter, ...
BioWorld4d
Veru weight loss study hits primary endpoint, stock drops
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). The side effect of lean mass ...
Investing6d
Oppenheimer maintains Veru stock Outperform rating as trial nears
InvestingPro data shows the stock has demonstrated strong resilience, often moving independently of broader market trends. The focus is on the potential of enobosarm, Veru's investigational drug, to ...